Regulus Therapeutics
RGLS
#7116
Rank
ยฃ0.41 B
Marketcap
ยฃ6.01
Share price
0.00%
Change (1 day)
424.82%
Change (1 year)

Earnings for Regulus Therapeutics (RGLS)

Earnings in 2025 (TTM): -ยฃ36.82 Million

According to Regulus Therapeutics's latest financial reports the company's current earnings are N/A. In 2024 the company made an earning of -ยฃ34.04 Million a decrease over its 2023 earnings that were of -ยฃ21.68 Million. The earnings displayed on this page is the company's Pretax Income.

Earnings history for Regulus Therapeutics from 2012 to 2025

Annual earnings

Year Earnings Change
2025 (TTM) -ยฃ36.82 Million8.17%
2024 -ยฃ34.04 Million56.97%
2023 -ยฃ21.68 Million6.51%
2022 -ยฃ20.36 Million2.53%
2021 -ยฃ19.86 Million93.59%
2020 -ยฃ10.26 Million-15.41%
2019 -ยฃ12.13 Million-64.46%
2018 -ยฃ34.11 Million-33.26%
2017 -ยฃ51.11 Million-13.98%
2016 -ยฃ59.42 Million44.77%
2015 -ยฃ41.04 Million-1.63%
2014 -ยฃ41.73 Million203.6%
2013 -ยฃ13.75 Million8.65%
2012 -ยฃ12.65 Million

Earnings for similar companies or competitors

Company Earnings Earnings differencediff. Country
Sanofi
SNY
ยฃ5.67 B-16,333.32%๐Ÿ‡ซ๐Ÿ‡ท France
Biogen
BIIB
ยฃ1.14 B-3,381.75%๐Ÿ‡บ๐Ÿ‡ธ USA
Bristol-Myers Squibb
BMY
ยฃ6.87 B-19,767.29%๐Ÿ‡บ๐Ÿ‡ธ USA
AstraZeneca
AZN
ยฃ10.39 B-29,845.51%๐Ÿ‡ฌ๐Ÿ‡ง UK
GSK plc
GSK
ยฃ7.28 B-20,964.39%๐Ÿ‡ฌ๐Ÿ‡ง UK
Sangamo Therapeutics
SGMO
-ยฃ80.31 Million 129.87%๐Ÿ‡บ๐Ÿ‡ธ USA
Dicerna Pharmaceuticals
DRNA
-ยฃ86.67 Million 148.06%๐Ÿ‡บ๐Ÿ‡ธ USA
Alnylam Pharmaceuticals
ALNY
ยฃ0.42 B-1,313.98%๐Ÿ‡บ๐Ÿ‡ธ USA